Schizophrenia Clinical Trials in Seattle

View 11 new treatments for Schizophrenia in Seattle, WA, and nearby areas, such as Bellevue, Everett, Kent and Renton. Every day, Power helps hundreds of schiz patients connect with leading medical research.

RL-007 for Cognitive Impairment in Schizophrenia

Recognify Life Sciences Clinic, Everett + 2 more

This trial is testing a new drug, RL-007, to see if it can help people with schizophrenia think and remember better. The study will compare different doses of the drug and check for any side effects. Participants will take the drug for several weeks and complete memory and thinking tests before and after the treatment.Show More

Verified

Recruiting
Phase 2
Est. 3 - 6 Weeks
Gary Walker, PhD
Study Director

KarXT for Schizophrenia

Karuna Clinic, Bellevue + 1 more

This trial tests KarXT, a combination of two drugs, for people who haven't improved with their current treatment. KarXT aims to balance brain functions and reduce side effects. The study will look at improvements in health and daily life. KarXT has shown positive results in earlier tests.Show More
Recruiting
Phase 3
Est. 3 - 6 Weeks
Ronald Marcus, MD
Study Director

Long-term Safety of Iclepertin for Schizophrenia

Boehringer Ingelheim Clinic, Bellevue + 1 more

This study is open to adults with schizophrenia who took part in a previous CONNEX study (study 1346-0011, 1346-0012, or 1346-0013). The purpose of this study is to find out how well people with schizophrenia can tolerate a medicine called Iclepertin in the long term. Participants take Iclepertin as tablets once a day for 1 year. In addition, all participants take their normal medication for schizophrenia. Participants are in the study for a little more than 1 year. During this time, they visit the study site about 13 times and get about 9 phone calls from the study team. The doctors collect information on any health problems of the participants. Doctors also regularly check the participants' symptoms of schizophrenia.Show More
Recruiting

No Placebo Trial

Phase 3
Est. 6 - 12 Weeks
Unregistered Study Lead
Research Team

KarXT for Schizophrenia

Karuna Clinic, Bellevue + 2 more

This trial tests the safety and tolerability of KarXT, a combination of two drugs, in schizophrenia patients who haven't responded well to their current treatments. KarXT aims to improve symptoms and manage side effects better than existing medications. KarXT (xanomeline plus trospium) is an emerging treatment for schizophrenia, showing promise in managing total, positive, and negative symptoms.Show More
Recruiting

No Placebo Trial

Phase 3
Est. 3 - 12 Weeks
Bristol-Myers Squibb
Study Director

Iclepertin for Schizophrenia

Boehringer Ingelheim Clinic, Everett + 1 more

This trial tests if a medicine called Iclepertin can help improve memory and learning in adults with schizophrenia. Participants take Iclepertin daily while continuing their usual medication. Doctors regularly check their mental abilities and health throughout the study. Iclepertin is being studied for its potential to improve cognitive functions in schizophrenia.Show More
Recruiting
Phase 3
Est. 3 - 12 Weeks
Unregistered Study Lead
Research Team

Dexmedetomidine for Agitation in Schizophrenia and Bipolar Disorder

BioXcel Clinic, Everett + 1 more

In this study, an investigational medication named BXCL501 is being tested for the treatment of episodes of agitation associated with bipolar I and bipolar II disorder, schizophrenia, schizoaffective and schizophreniform disorder. This study compares the study drug to a placebo.Show More
Waitlist
Phase 3
Est. 3 - 12 Weeks
Robert Risinger, MD
Study Chair

OLZ/SAM for Schizophrenia

Alkermes Clinic, Everett + 1 more

This trial evaluates the safety and tolerability of OLZ/SAM in children and adolescents with schizophrenia or Bipolar I disorder. OLZ/SAM combines olanzapine to manage symptoms and samidorphan to reduce weight gain. Olanzapine is a well-established antipsychotic effective for schizophrenia and bipolar I disorder, but its use is limited by significant weight gain; samidorphan is added to mitigate this side effect.Show More
Waitlist

No Placebo Trial

Phase 3
Est. 3 - 12 Weeks
David McDonnell, MD
Study Director

OLZ/SAM vs. Olanzapine for Schizophrenia or Bipolar Disorder

Alkermes Clinic, Everett + 1 more

To compare changes in body mass index (BMI) Z-score following treatment with OLZ/SAM vs olanzapine
Recruiting

No Placebo Trial

Phase 3
Est. 3 - 6 Weeks
David McDonnell, MD
Study Director

Iclepertin for Schizophrenia

Boehringer Ingelheim Clinic, Bellevue + 1 more

This trial tests if a daily pill called Iclepertin can improve learning and memory in adults with schizophrenia. Participants take either Iclepertin or another pill for several months while continuing their usual medication. Doctors regularly check their mental abilities and overall health.Show More
Recruiting
Phase 3
Est. 6 - 12 Weeks
Unregistered Study Lead
Research Team

mHealth Intervention for Schizophrenia

Research Clinic, Everett + 3 more

Randomized control trial examining two mHealth intervention strategies.
Waitlist

No Placebo Trial

N/A
Est. 4 - 6 Weeks
Dror Ben-Zeev, PhD
Principal Investigator
Page 1 of 2

Frequently Asked Questions